ABBV
Price
$183.14
Change
-$2.35 (-1.27%)
Updated
Jun 23, 01:46 PM (EDT)
Capitalization
322.43B
32 days until earnings call
RHHBF
Price
$340.40
Change
-$2.34 (-0.68%)
Updated
Jun 18 closing price
Capitalization
250.69B
Interact to see
Advertisement

ABBV vs RHHBF

Header iconABBV vs RHHBF Comparison
Open Charts ABBV vs RHHBFBanner chart's image
ABBVIE
Price$183.14
Change-$2.35 (-1.27%)
Volume$793
Capitalization322.43B
Roche Holding
Price$340.40
Change-$2.34 (-0.68%)
Volume$2
Capitalization250.69B
ABBV vs RHHBF Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. RHHBF commentary
Jun 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and RHHBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2025
Stock price -- (ABBV: $185.49 vs. RHHBF: $340.40)
Brand notoriety: ABBV: Notable vs. RHHBF: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 0% vs. RHHBF: 3%
Market capitalization -- ABBV: $322.43B vs. RHHBF: $250.69B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. RHHBF’s [@Pharmaceuticals: Major] market capitalization is $250.69B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 3 FA rating(s) are green whileRHHBF’s FA Score has 2 green FA rating(s).

  • ABBV’s FA Score: 3 green, 2 red.
  • RHHBF’s FA Score: 2 green, 3 red.
According to our system of comparison, ABBV is a better buy in the long-term than RHHBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 6 TA indicator(s) are bullish.

  • ABBV’s TA Score: 6 bullish, 4 bearish.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -2.93% price change this week, while RHHBF (@Pharmaceuticals: Major) price change was +0.86% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.64%. For the same industry, the average monthly price growth was +3.31%, and the average quarterly price growth was +6.93%.

Reported Earning Dates

ABBV is expected to report earnings on Jul 25, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.64% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($322B) has a higher market cap than RHHBF($251B). ABBV has higher P/E ratio than RHHBF: ABBV (66.46) vs RHHBF (21.19). RHHBF YTD gains are higher at: 13.023 vs. ABBV (6.342). RHHBF has higher annual earnings (EBITDA): 19.1B vs. ABBV (17.2B). ABBV has more cash in the bank: 12.8B vs. RHHBF (7.51B). RHHBF has less debt than ABBV: RHHBF (25.4B) vs ABBV (59.4B). RHHBF has higher revenues than ABBV: RHHBF (60B) vs ABBV (54.3B).
ABBVRHHBFABBV / RHHBF
Capitalization322B251B128%
EBITDA17.2B19.1B90%
Gain YTD6.34213.02349%
P/E Ratio66.4621.19314%
Revenue54.3B60B91%
Total Cash12.8B7.51B170%
Total Debt59.4B25.4B234%
FUNDAMENTALS RATINGS
ABBV vs RHHBF: Fundamental Ratings
ABBV
RHHBF
OUTLOOK RATING
1..100
3450
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
16
Undervalued
PROFIT vs RISK RATING
1..100
12100
SMR RATING
1..100
1499
PRICE GROWTH RATING
1..100
5448
P/E GROWTH RATING
1..100
1416
SEASONALITY SCORE
1..100
4575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RHHBF's Valuation (16) in the null industry is in the same range as ABBV (46) in the Pharmaceuticals Major industry. This means that RHHBF’s stock grew similarly to ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBF (100) in the null industry. This means that ABBV’s stock grew significantly faster than RHHBF’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBF (99) in the null industry. This means that ABBV’s stock grew significantly faster than RHHBF’s over the last 12 months.

RHHBF's Price Growth Rating (48) in the null industry is in the same range as ABBV (54) in the Pharmaceuticals Major industry. This means that RHHBF’s stock grew similarly to ABBV’s over the last 12 months.

ABBV's P/E Growth Rating (14) in the Pharmaceuticals Major industry is in the same range as RHHBF (16) in the null industry. This means that ABBV’s stock grew similarly to RHHBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBV
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
61%
Momentum
ODDS (%)
Bearish Trend 4 days ago
47%
MACD
ODDS (%)
Bearish Trend 4 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
48%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
52%
Advances
ODDS (%)
Bullish Trend 12 days ago
56%
Declines
ODDS (%)
Bearish Trend 7 days ago
46%
BollingerBands
ODDS (%)
Bullish Trend 8 days ago
64%
Aroon
ODDS (%)
Bullish Trend 4 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRVFX42.870.06
+0.14%
Franklin Small Cap Value C
MUOIX30.34-0.04
-0.13%
Morgan Stanley Instl US Core I
CAIBX74.77-0.13
-0.17%
American Funds Capital Income Bldr A
RINTX47.03-0.45
-0.95%
Russell Inv International Devd Mkts S
LDVCX25.30-0.37
-1.44%
AXS FTSE Vntr Cptl RetTrckr C

RHHBF and

Correlation & Price change

A.I.dvisor tells us that RHHBF and RHHBY have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RHHBF and RHHBY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBF
1D Price
Change %
RHHBF100%
N/A
RHHBY - RHHBF
32%
Poorly correlated
-1.06%
RHHVF - RHHBF
25%
Poorly correlated
-2.44%
NVS - RHHBF
20%
Poorly correlated
-0.16%
JNJ - RHHBF
16%
Poorly correlated
-0.62%
ABBV - RHHBF
16%
Poorly correlated
N/A
More